NCAM1 and breast carcinoma: Supporting the notion that HER2 trogocytosis is specific to HER2+ breast cancer, only low levels of HER2 expression were observed on the CD14+ and CD56+ cells of luminal type tumors (Additional file 2: Figures S2A and B; luminal type tumor).